Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

Prostate

Volumn 44, Issue 2, 2000, Pages 172-180

  Plonowski, Artur ^a,b,c   Schally, Andrew V ^a,b   Varga, Jozsef L ^a,b   Rekasi, Zoltan ^a,b   Hebert, Francine ^a   Halmos, Gabor ^a,b   Groot, Kate ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Androgen independent prostate cancer; Antagonist of bombesin gastrin releasing peptide; Antagonist of growth hormone releasing hormone; Epidermal growth factor; Insulin like growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; BOMBESIN ANTAGONIST; EPIDERMAL GROWTH FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; JV 138; MZ 5 156; RC 3940; SOMATOMEDIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER INHIBITION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BOMBESIN; CELL LINE; DNA PRIMERS; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-RELEASING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SERMORELIN; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR CELLS, CULTURED;

EID: 0034234650     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000701)44:2<172::AID-PROS10>3.0.CO;2-Z     Document Type: Article

References (42)

1. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E III, Bast RC Jr, Kufe DE, Morton DL, Weichselbaum RR, editors. Cancer medicine, 4th ed. Baltimore: Williams and Wilkins; 1947. p 1067-1086
2. Oh WK, Kantoff PW. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin Oncol 1999;26:49-54.
3. Salgaller ML, Lodge PA, Tjoa BA, Simmons SJ, Jarisch J, Baden RR, Kelley HJ, McLean JC, Ragde H, Kenny RJ, Rogers M, Boyton AL, Murphy GP. Demonstration of in vivo and in vitro immune responses in phase II clinical trial following infusion of dendritic cells pulsed with prostate-specific membrane antigen-(PSMA) derived peptides into patients with early and advanced prostate cancer. In: 99th Annual Meeting of the American Association for Cancer Research; 1999 April 10-14; Philadelphia. Philadelphia: American Association for Cancer Research; 1999. p 409.
4. Festuccia C, Guerra F, D'Ascenzo S, Giunciuglio D, Albini A, Bologna M. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 1998; 75:418-431.
5. Hoosein NN, Logothetis CJ, Chung LWK. Differential effects of peptide hormones bombesin, vasoactive intestinal peptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
6. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-1159.
7. 2 showing high binding affinity to bombesin/GRP receptors on CFPAC-1 human pancreatic cancer cell line. Int J Oncol 1995;6: 1165-1172.
8. Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit growth and decrease the level and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer 1998;83:1335-1343.
9. Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res 1994;54:169-174.
10. Pinski J, Schally AV, Halmos G, Szepeshazi K. Effect of somatostatin analog RC-160 and bombesin/gastrin-reteasing peptide antagonist RC-3095 on growth of PC-3 human prostate cancer xenografts in nude mice. Int J Cancer 1993;55:963-967.
11. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 1997;33:1141-1148.
12. Foster BA, Kaplan PJ, Greenberg NM. Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev 1999;17:317-324.
13. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994;54:5474-5478.
14. Sherwood ER, Van Dongen JL, Wood CG, Jiao S, Kozlowski JM, Lee C. Epidermal growth factor receptors activation in androgen independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998;77:855-861.
15. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-566.
16. Wolk A, Mantzoros CS, Andersson SO, Bergstron R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90;911-915.
17. Schally AV, Varga JL. Antagonistic analogs of growth hormone-releasing hormone (GH-RH): new potential antitumor agents. Trends Endocrinol Metab 1999;10:383-391.
18. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Vadillo-Buenfil M. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 1997;75:1585-1592.
19. Csernus VJ, Schally AV, Kiaris H, Armatis P. Inhibition of growth, production of insulin-like growth factor II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone. Proc Natl Acad Sci USA 1999;96:3098-3103.
20. Lamharzi N, Schally AV, Koppan M, Groot K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 1998;95:8864-8868.
21. Varga JL, Schally AV, Csernus V, Zarandi M, Halmos G, Groot K, Rekasi Z. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA 1999;96:692-697.
22. Zarandi M, Kovacs M, Horvath JE, Toth K, Halmos G, Groot K, Nagy A, Kele Z, Schally AV. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone. Peptides 1997;18:423-430.
23. Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, Czompoly T. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 2000; in press.
24. Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guijarro LG, Prieto JC. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Endocrinology 1996;137:2815-2822.
25. Westin P, Stattin P, Damber JE, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995;146:1368-1375.
26. Craft N, Sawyers C. Mechanistic concepts in androgen-independence of prostate cancer. Cancer Metastasis Rev 1999; 17:421-427.
27. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G, Klocker H. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 1997;32:106-114.
28. 1) receptor: three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Biol Chem 1996;271:12795-12800.
29. 1 subtype is predominant in rat prostate membranes. Prostate 1999;41:1-6.
30. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implication for tumor imaging. J Nucl Med 1995;36:1846-1853.
31. Nakagawa K, Ishizuka T, Shimizu C, Matsuura Y, Wada N, Kijima H, Ito Y, Aida T, Abe H. cAMP production by GHRH in GH-producing pituitary adenoma. Horm Metab Res 1992;24: 446-447.
32. Jiang S, Kopras E, McMichael M, Bell RH Jr, Ulrich CD II. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res 1997;57:1475-1480.
33. Post GR, Brown JH. G protein coupled receptors and signaling pathways regulating growth responses. FASEB J 1996;10:741-749.
34. Gaylinn BD. Molecular and cell biology of the growth hormone-releasing hormone receptor. Growth Horm IGF Res 1999;9:37-44.
35. Nazareth LV, Weigel NL. Activation of human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271:19900-19907.
36. Voutilainen R, Miller WL. Coordinate tropic regulation of mRNAs for insulin-like growth factor II and the cholesterol side-chain-cleavage enzyme, P450 scc in human steroidogenic tissues. Proc Natl Acad Sci USA 1987;84:1590-1594.
37. Voutilainen R, Miller WL. Developmental and hormonal regulation of mRNAs for insulin-like growth factor II and steroidogenic enzymes in human fetal adrenals and gonads. DNA 1988; 7:9-15.
38. Cadoret A, Baron-Delage S, Bertrand F, Kornpost M, Groyer A, Gespach C, Capeau J, Cherqui G. Oncogene-induced up-regulation of Caco-2 cell proliferation involves IGF-II gene activation through a protein kinase C-mediated pathway. Oncogene 1998;17:877-887.
39. Chen T, Cho RW, Stork PJ, Weber MJ. Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 1999;59:213-218.
40. Putz T, Cullig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, Klocker H. Epidermal growth factor (EGF) receptor blockade inhibits the activation of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999;59:227-233.
41. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-284.
42. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-2897.